An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 Following a Single Oral Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2019
Price : $35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 25 Sep 2017 Status changed from active, no longer recruiting to completed.
- 22 May 2017 Planned End Date changed from 2 Jul 2018 to 7 Jun 2018.
- 22 May 2017 Planned primary completion date changed from 14 Jun 2017 to 22 May 2017.